top of page

Pharma Exports from India: Key Markets, Products & Future Outlook

India has earned its place on the global map as the “Pharmacy of the World”, and rightly so. With one of the largest generic drug industries and a robust network of WHO-GMP-compliant facilities, India is the third-largest producer of pharmaceuticals by volume and among the top 10 exporters globally.

In FY 2023-24, India’s pharmaceutical exports stood at USD 27.9 billion, with growth driven by affordability, regulatory compliance, and global trust in Indian manufacturers.

Let’s explore the key markets, major exported products, and the future outlook of India’s pharma export landscape.


Pharma Exports from India


🌍 Key Export Markets for Indian Pharma


Indian pharmaceutical products reach over 200 countries, with major markets including:


1. United States 🇺🇸

  • The largest destination for Indian generics (over 30% of total exports)

  • India has the highest number of FDA-approved plants outside the US

  • Key products: generic oncology, anti-infectives, antidiabetics


2. Africa 🌍

  • Countries like Nigeria, Kenya, and South Africa import significant volumes

  • Key products: antiretrovirals (ARVs), antibiotics, malaria drugs

  • India plays a vital role in global health programs like PEPFAR & Global Fund


3. European Union 🇪🇺

  • Stringent regulatory compliance (EMA, EU-GMP)

  • Major importers: UK, Germany, Netherlands

  • Products: generic cardiovascular and CNS drugs, nutraceuticals


4. South-East Asia & Latin America 🌎

  • Philippines, Vietnam, Brazil, and Mexico emerging as high-potential markets

  • Local regulatory partnerships and branded generics model popular here


5. CIS Countries & Middle East 🌐

  • Demand for high-quality, affordable Indian generics remains strong

  • Government-to-government agreements boosting institutional supply


💊 Top Exported Products by India

Indian exports cover a vast range of pharmaceutical products. Key segments include:


🔹 Generic Formulations (70% of exports)

  • Tablets, capsules, injectables, syrups

  • Chronic therapy: diabetes, hypertension, cancer, HIV

  • Acute therapy: antibiotics, pain relief, antipyretics


🔹 APIs (Active Pharmaceutical Ingredients)

  • Exported to formulation manufacturers across Europe, China, and the US

  • India is a leading API producer for paracetamol, metformin, and ibuprofen


🔹 OTC Products & Nutraceuticals

  • Growing demand in the US, EU, and Middle East for herbal, ayurvedic, and wellness products


🔹 Vaccines & Biologics

  • India is a top global vaccine supplier (e.g., Serum Institute)

  • COVID-19 vaccine diplomacy elevated India’s image globally


🚀 Future Outlook for Indian Pharma Exports


✅ 1. Rising Global Demand for Generics

  • Global patent cliffs expected between 2025-2030 will create new generic opportunities

  • India is poised to capture a large share of this wave


✅ 2. Shift to Value-Added Products

  • Growth in complex generics, biosimilars, injectables, and novel drug delivery systems (NDDS)


✅ 3. Strategic Trade Agreements

  • Free Trade Agreements (FTAs) with the UK, Canada, Australia can open new channels


✅ 4. Diversification of API Manufacturing

  • Government incentives for domestic API production will reduce dependency on China and strengthen the backend of exports


✅ 5. Regulatory Harmonization & Tech Upgradation

  • Digitalization of quality control and compliance through AI, blockchain, and data analytics

  • Continued investment in regulatory certifications (USFDA, EMA, WHO-GMP)


🏭 Partner with an Export-Ready Manufacturer

At Suncare Formulations Pvt Ltd, we have been proudly contributing to India’s global pharma footprint for over 30 years. We are a WHO-GMP-certified manufacturer with twin state-of-the-art plants based in Dehradun, with a track record of working with top names like Lupin, Cadila, Micro Labs, and multiple government contracts including Jan Aushadhi and DRDO.


Our export-oriented capabilities include:


  • Over 400 formulations across 60 therapeutic areas

  • Flexible production in tablets, capsules, liquids, externals

  • Compliance with global regulatory standards


🔗 Learn more about our work: www.suncareformulations.com


🤝 Industry Leadership Matters


Our Director, Mr. Sanjay Sikaria, serves as:

  • Secretary, Drug Manufacturers Association (Dehradun)

  • Secretary, Federation of Pharma Entrepreneurs (FOPE)

  • Director, TIE Dehradun and Uni-Scientific Analytical Research Foundation


He is also a key figure behind the upcoming Common Facility Centre in Uttarakhand, further supporting industry innovation and collaboration.

Comments

bottom of page